BIOMAT Database Logo BIOMAT Database Logo

Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. 1988

J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Metabolism Branch, National Cancer Institute, Bethesda, Maryland 20892.

T-lymphocyte immunity is likely to be an important component of the immune defence against the AIDS virus, because helper T cells are necessary for the antibody response as well as the cytotoxic response. We have previously predicted two antigenic sites of the viral envelope protein gp120 likely to be recognized by T lymphocytes, based on their ability to fold as amphipathic helices, and have demonstrated that these are recognized by T cells of mice immunized with gp120 (ref. 1). A peptide corresponding to one of these sites can also be induce immunity in mice to the whole gp120 protein. Because many clinically healthy seropositive blood donors have already lost their T-cell proliferative response to specific antigen, we tested the response to these synthetic peptides of lymphocytes from 14 healthy human volunteers who had been immunized with a recombinant vaccinia virus containing the AIDS viral envelope gene and boosted with a recombinant fragment. Eight of the 14 responded to one peptide, and four to the other peptide, not included in the boost. These antigenic sites recognized by human T cells may be useful components of a vaccine against AIDS. We also found a correlation between boosting with antigen-antibody complexes (compared to free antigen) and higher stimulation indices, suggesting a more effective method of immunization.

UI MeSH Term Description Entries
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen

Related Publications

J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Antigenic structures recognized by cytotoxic T lymphocytes.
February 1991, The Journal of biological chemistry,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.
January 1993, Vaccine,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes.
February 1998, The Journal of experimental medicine,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Tumor-specific shared antigenic peptides recognized by human T cells.
October 2002, Immunological reviews,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer.
August 2001, Human immunology,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Naturally processed viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human immunodeficiency virus type 1.
October 1994, The Journal of experimental medicine,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells.
August 2002, Japanese journal of cancer research : Gann,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Melanocortin 1 Receptor-derived peptides are efficiently recognized by cytotoxic T lymphocytes from melanoma patients.
March 2014, Immunobiology,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Identification of viral molecules recognized by influenza-specific human cytotoxic T lymphocytes.
February 1987, The Journal of experimental medicine,
J A Berzofsky, and A Bensussan, and K B Cease, and J F Bourge, and R Cheynier, and Z Lurhuma, and J J Salaün, and R C Gallo, and G M Shearer, and D Zagury
Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
September 1999, Journal of immunology (Baltimore, Md. : 1950),
Copied contents to your clipboard!